# A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria

> **NCT05129423** · PHASE2 · WITHDRAWN · sponsor: **Genentech, Inc.**

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** MTPS9579A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05129423
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-07-31
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Development of MTPS9579A was terminated for strategic/business reasons.
- **Last updated:** 2022-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05129423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05129423, "A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05129423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*